5 Firms Build Migraine-Focused TriGemX's $600M SPAC Deal

Дата публикации: 19-10-2026 20:28:56

Biotechnology company TriGemX Bio on Monday unveiled plans to go public by merging with special purpose acquisition company TCGX Acquisition Corp. in a deal built by five law firms that creates a combined company with a $600 million post-transaction equity value.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	5 Firms Build Migraine-Focused TriGemX's $600M SPAC Deal	0	13.33	19-10-2026
2	3 Firms Steer Cargo Drone Co.'s $800M SPAC Merger	0	5	26-06-2026
3	City Therapeutics' Upsized $200M IPO Joins Biotech Wave	0	10.86	16-10-2026
4	5 Firms Steer $3.4B Silgan, Trivium Packaging Deal	0	11.32	19-10-2026
5	3 Firms Guide Reusable Spacecraft Maker's $380M SPAC Deal	0	11.7	06-08-2026
6	Clean Energy Data Center Developer Inks $300M SPAC Merger	0	11.59	09-10-2026
7	2 Firms Lead Merck's $11.3B Bio-Techne Life Sciences Deal	0	7	25-06-2026
8	United Therapeutics Buys Thymmune For Up To $300M	0	5	02-07-2026
9	Tarsus Bets Up To $800M On Alkeus In Retina Therapy Push	0	10	06-08-2026
10	BSTR Ends $1.5B SPAC Deal Amid Bitcoin Market Woes	0	10.41	21-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.33. Источник: www.law360.com.